In , Lincoln Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +48.1% relative strength. Fundamentals: Average. On a 12-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +13% | +10% | Stable |
| PAT (Net Profit) | +38% | +6% | Inflection Up |
| OPM | 14.0% | -200 bps | Stable |
Based on publicly available financial data. This is educational research, not investment advice.
Lincoln Pharmaceuticals Ltd's latest quarterly results (Dec 2025) show
Lincoln Pharmaceuticals Ltd's profit is growing with an turning around (inflection up) trend.
Lincoln Pharmaceuticals Ltd's revenue growth trend is stable.
Lincoln Pharmaceuticals Ltd's operating margin is stable.
Lincoln Pharmaceuticals Ltd's long-term compounding rates
Lincoln Pharmaceuticals Ltd's earnings growth is turning around (inflection up) with mixed signals on a sequential basis.
Lincoln Pharmaceuticals Ltd's trailing twelve month (TTM) performance
Lincoln Pharmaceuticals Ltd appears fairly valued based on our fair value analysis.
Lincoln Pharmaceuticals Ltd's current PE ratio is 15.4x.
Lincoln Pharmaceuticals Ltd's current PE is 15.4x.
Lincoln Pharmaceuticals Ltd's price-to-book ratio is 1.9x.
Lincoln Pharmaceuticals Ltd is rated Average with a fundamental score of 56.79/100. This score is calculated from objective financial metrics
Lincoln Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
Lincoln Pharmaceuticals Ltd's return ratios over recent years
Lincoln Pharmaceuticals Ltd's operating cash flow is positive (FY2025).
Lincoln Pharmaceuticals Ltd's current dividend yield is 0.27%.
Lincoln Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
Lincoln Pharmaceuticals Ltd's promoter holding has remained stable recently.
Lincoln Pharmaceuticals Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Lincoln Pharmaceuticals Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Lincoln Pharmaceuticals Ltd may be worth studying
Lincoln Pharmaceuticals Ltd investment thesis summary:
Lincoln Pharmaceuticals Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
